Czech National Bank Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Czech National Bank increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,854 shares of the medical research company's stock after purchasing an additional 4,920 shares during the quarter. Czech National Bank's holdings in Thermo Fisher Scientific were worth $43,716,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Cypress Advisory Group LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $253,000. Intact Investment Management Inc. grew its stake in shares of Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after purchasing an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $1,121,000. Independence Bank of Kentucky lifted its holdings in Thermo Fisher Scientific by 21.0% during the 4th quarter. Independence Bank of Kentucky now owns 3,825 shares of the medical research company's stock worth $1,990,000 after buying an additional 663 shares during the last quarter. Finally, W.H. Cornerstone Investments Inc. increased its holdings in shares of Thermo Fisher Scientific by 25.1% in the 4th quarter. W.H. Cornerstone Investments Inc. now owns 2,870 shares of the medical research company's stock valued at $1,493,000 after acquiring an additional 576 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $3.22 during mid-day trading on Thursday, reaching $400.44. The stock had a trading volume of 1,287,637 shares, compared to its average volume of 1,893,707. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The business has a 50 day simple moving average of $424.35 and a 200 day simple moving average of $497.38. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The firm has a market capitalization of $151.16 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.11 earnings per share. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. UBS Group decreased their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Argus cut their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.